The American Cancer Society’s new guidelines add blood-based and expanded at-home testing options as Latino communities face rising early-onset colorectal cancer rates and persistent screening challenges.
The American Cancer Society has officially expanded its colon cancer screening recommendations for the first time in years, adding new blood-based and advanced at-home testing options that could make screening more accessible for millions of Americans, especially Latino communities that continue to face lower screening rates and rising early-onset colorectal cancer cases.
The updated guidance, released May 27, keeps the recommended screening age at 45 for average-risk adults. But the biggest change is the addition of the FDA-approved Shield blood test and newer stool-based tests such as Cologuard Plus and ColoSense.
The changes arrive at a critical moment for California’s Latino population. Research from the American Cancer Society, National Institutes of Health, and Centers for Disease Control and Prevention shows Latinos are more likely to delay screenings, more likely to be diagnosed at later stages, and increasingly affected by colorectal cancer before age 50.
For many families in Los Angeles and across California, the update could lower some of the cultural, emotional, and logistical obsticles that have historically kept people from getting screened.
Colorectal cancer is now one of the deadliest cancers affecting Latinos in the United States.
According to the American Cancer Society, it is the second leading cause of cancer death among Latino men and the third most common among Latina women. At the same time, younger Latinos are seeing some of the fastest increases in early-onset colorectal cancer in the country.
Researchers say multiple factors contribute to the disparity.
Some Latino men report embarrassment or discomfort around colonoscopies because of cultural stigma tied to masculinity and invasive medical procedures. Other studies point to fear, fatalismo, language barriers, lack of insurance, inflexible work schedules, and limited access to specialists.
Many patients also prefer at-home stool tests because they avoid sedation, bowel preparation, and time away from work.
That matters in California, where many low-income workers juggle multiple jobs, lack paid sick leave, or face transportation challenges to medical appointments.
What Changed in the 2026 Colon Cancer Guidelines?
The new guidelines expand the list of approved screening options for average-risk adults age 45 and older.
The American Cancer Society emphasized a simple but important message: the best screening test is the one patients actually complete.
The Full List of Screening Options
Colonoscopy
Still considered the most comprehensive screening method because doctors can directly detect and remove precancerous polyps during the procedure.
Recommended every 10 years for average-risk adults.
Stool-Based Testing
Includes:
- Cologuard Plus
- ColoSense
- FIT tests
- gFOBT tests
These tests are completed at home and mailed to a lab.
FIT and stool blood tests are generally recommended every year. Multitarget molecular stool tests like Cologuard Plus and ColoSense are recommended every three years.
New Blood-Based Testing
The biggest headline is the inclusion of the Shield blood test.
The test uses a standard blood draw performed in a medical office every three years. It is intended for adults who decline colonoscopy or stool testing.
Doctors say the blood test could help increase participation among people who avoid traditional screening methods because of fear, embarrassment, or scheduling barriers.
The Important Catch Most People Miss
A positive stool or blood test is not the end of the process.
If results come back abnormal, patients must still complete a follow-up colonoscopy to confirm whether cancer or precancerous growths are present.
That follow-up procedure is essential because it allows doctors to remove polyps before they become cancerous.
This distinction matters because some patients mistakenly believe the blood or stool test completely replaces colonoscopy. It does not.
Insurance Coverage Could Shape Who Actually Benefits
Coverage differences may determine whether these new options truly improve screening access in California.
Medicare Coverage
Medicare Part B now covers:
- Cologuard and similar stool tests at no cost
- The Shield blood test every three years
- Follow-up colonoscopies after abnormal results
This could significantly expand access for older Latino adults.
Medi-Cal Coverage in California
California’s Medi-Cal program already covers FIT tests and stool-based screening options with no copay.
But there is a major gap.
The new Shield blood test is currently not covered by Medi-Cal or Medicaid programs. Without coverage, patients could face out-of-pocket costs ranging from roughly $895 to nearly $1,500.
That creates a two-tier system where Medicare patients can access the new blood test for free while many low-income Californians cannot.
Healthcare advocates say that gap could disproportionately affect Latino communities in Los Angeles County, where Medi-Cal enrollment is especially high.
Why Early Detection Is Becoming More Urgent
Doctors are increasingly alarmed by the rise in colorectal cancer among younger adults.
Latinos now have the highest percentage of early-onset colorectal cancer diagnoses among major racial and ethnic groups studied in the U.S.
Researchers believe changes tied to diet, sedentary lifestyles, obesity, and processed food consumption may be contributing factors. Studies also show colorectal cancer rates tend to rise among Latino immigrants after years living in the United States.
Puerto Rican communities have seen especially high early-onset rates, while Mexican, Central American, and South American descendants also show elevated percentages of diagnoses before age 50.
Because many younger adults do not expect cancer symptoms at their age, diagnoses often happen later, when treatment becomes more difficult and survival rates decline.
Healthcare systems across California will now face pressure to expand education and outreach around the new screening choices.
Public health experts say awareness matters because many people still do not know screening now begins at age 45 instead of 50.
Los Angeles County clinics and community health organizations may also increase promotion of stool-based testing because those options remain the most affordable and widely covered under Medi-Cal.
At the same time, advocates will likely push California Medicaid officials to eventually cover blood-based testing so lower-income patients are not excluded from the newest screening technology.
For families hesitant about colonoscopies, doctors stress that doing some form of screening is far better than doing nothing at all.
Zul Surani: Medical trials, the path to new medications and treatments
